Article

Characteristics of Opioid-Users Whose Death Was Related to Opioid-Toxicity: A Population-Based Study in Ontario, Canada

Division of Clinical Pharmacology and Toxicology, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
PLoS ONE (Impact Factor: 3.53). 04/2013; 8(4):e60600. DOI: 10.1371/journal.pone.0060600
Source: PubMed

ABSTRACT The impact of the prescription opioid public health crisis has been illustrated by the dramatic increase in opioid-related deaths in North America. We aimed to identify patterns and characteristics amongst opioid-users whose cause of death was related to opioid toxicity.
This was a population-based study of Ontarians between the years 2006 and 2008. All drug-related deaths which occurred during this time frame were reviewed at the Office of the Chief Coroner of Ontario, and opioid-related deaths were identified. Medical, toxicology, pathology, and police reports were comprehensively reviewed. Narratives, semi-quantitative, and quantitative variables were extracted, tabulated, and analyzed.
Out of 2330 drug-related deaths in Ontario, 58% were attributed either in whole or in part, to opioids (n = 1359). Oxycodone was involved in approximately one-third of all opioid-related deaths. At least 7% of the entire cohort used opioids that were prescribed for friends and/or family, 19% inappropriately self-administered opioids (injection, inhalation, chewed patch), 3% were recently released from jail, and 5% had been switched from one opioid to another near the time of death. Accidental deaths were significantly associated with personal history of substance abuse, enrollment in methadone maintenance programs, cirrhosis, hepatitis, and cocaine use. Suicides were significantly associated with mental illness, previous suicide attempts, chronic pain, and a history of cancer. SIGNIFICANCECONCLUSION: These results identify novel, susceptible groups of opioid-users whose cause of death was related to opioids in Ontario and provide the first evidence to assist in quantifying the contribution of opioid misuse and diversion amongst opioid-related mortality in Canada. Multifaceted prevention strategies need to be developed based on subpopulations of opioid users.

Full-text

Available from: Parvaz Madadi, Jun 14, 2015
0 Followers
 · 
88 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: After participating in this activity, learners should be better able to: Evaluate the rationale for and current evidence supporting medication-assisted treatment of opioid use disorder. Medication-assisted treatment of opioid use disorder with physiological dependence at least doubles rates of opioid-abstinence outcomes in randomized, controlled trials comparing psychosocial treatment of opioid use disorder with medication versus with placebo or no medication. This article reviews the current evidence for medication-assisted treatment of opioid use disorder and also presents clinical practice imperatives for preventing opioid overdose and the transmission of infectious disease. The evidence strongly supports the use of agonist therapies to reduce opioid use and to retain patients in treatment, with methadone maintenance remaining the gold standard of care. Combined buprenorphine/naloxone, however, also demonstrates significant efficacy and favorable safety and tolerability in multiple populations, including youth and prescription opioid-dependent individuals, as does buprenorphine monotherapy in pregnant women. The evidence for antagonist therapies is weak. Oral naltrexone demonstrates poor adherence and increased mortality rates, although the early evidence looks more favorable for extended-release naltrexone, which has the advantages that it is not subject to misuse or diversion and that it does not present a risk of overdose on its own. Two perspectives-individualized treatment and population management-are presented for selecting among the three available Food and Drug Administration-approved maintenance therapies for opioid use disorder. The currently unmet challenges in treating opioid use disorder are discussed, as are the directions for future research.
    Harvard Review of Psychiatry 03/2015; 23(2):63-75. DOI:10.1097/HRP.0000000000000075 · 2.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prescription opioid analgesic (POA) utilization has steeply increased globally, yet is far higher in established market economies than elsewhere. Canada features the world's second-highest POA consumption rates. Following increases in POA-related harm, several POA control interventions have been implemented since 2010. We examined trends and patterns in POA dispensing in Canada by province for 2005-2012, including a focus on the potential effects of interventions. Data on annual dispensing of individual POA formulations - categorized into 'weak opioids' and 'strong opioids' - from a representative sub-sample of 5,700 retail pharmacies across Canada (from IMS Brogan's Compuscript) were converted into Defined Daily Doses (DDD), and examined intra- and inter-provincially as well as for Canada (total). Total POA dispensing - driven by strong opioids - increased across Canada until 2011; four provinces indicated decreases in strong opioid dispensing; seven provinces indicated decreases specifically in oxycodone dispensing, 2011-2012. The dispensing ratio weak/strong opioids decreased substantively. Major inter-provincial differences in POA dispensing levels and qualitative patterns of POA formulations dispensed persisted. Previous increasing trends in POA dispensing were reversed in select provinces 2011-2012, coinciding with POA-related interventions. Further examinations regarding the sustained nature, drivers and consequences of the recent trend changes in POA dispensing - including possible 'substitution effects' for oxycodone reductions - are needed.
    BMC Health Services Research 02/2014; 14(1):90. DOI:10.1186/1472-6963-14-90 · 1.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prescription opioid (POs, i.e. opioid analgesics requiring a prescription) related harms are extensive in North America; non-medical PO use (NMPOU), PO-related morbidity (e.g. hospital or treatment admissions) and mortality (e.g. overdose deaths) are high in the general population. Most recommendations towards reducing PO-related problems to date have focused on rather narrow and specific areas (e.g. improved PO monitoring, clinical PO use guidelines, detection of patients with PO abuse, tamper-resistant PO formulations). An integrated population health framework for POs – i.e. an evidence-based approach towards largest possible reductions of PO-related harms in the population, as is well established for other psychoactive drug (e.g. alcohol) fields – is currently missing. Recent PO-focused policy initiatives launched in Canada present long lists of recommendations – the feasibility and impact of which on PO-related harms is uncertain – yet also are notably silent on population health-based considerations or approaches. We outline select principal pillars – including general and targeted prevention, and treatment – for a population health framework for PO-related harms and offer suggestions for implementation, with Canada as the principal case study. Given the extensive burden and known population-level determinants of PO-related harms, the development of an evidence-based population health approach to reduce this burden is urgently advised.
    Drugs: Education Prevention and Policy 10/2014; 22(1). DOI:10.3109/09687637.2014.936827 · 0.53 Impact Factor